E Fund Management Co., Ltd. Cogent Biosciences, Inc. Transaction History

E Fund Management Co., Ltd.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$6.01 - $9.04 $133,031 - $200,100	-22,135 Reduced 66.46%	11,173 $94,000
Q1 2024 May 13, 2024	BUY	$4.38 - $9.02 $78,388 - $161,430	17,897 Added 116.13%	33,308 $223,000
Q4 2023 Feb 06, 2024	BUY	$4.06 - $10.08 $62,568 - $155,342	15,411 New	15,411 $90,000
Q2 2023 Aug 11, 2023	SELL	$9.85 - $13.24 $26,210 - $35,231	-2,661 Reduced 19.35%	11,088 $131,000
Q1 2023 May 11, 2023	SELL	$10.04 - $15.5 $32,389 - $50,003	-3,226 Reduced 19.0%	13,749 $148,000
Q4 2022 Feb 14, 2023	BUY	$10.65 - $14.84 $27,530 - $38,361	2,585 Added 17.96%	16,975 $196,000
Q3 2022 Nov 14, 2022	BUY	$9.39 - $16.99 $135,122 - $244,486	14,390 New	14,390 $215,000

172

114M

56.7K

40.4K

Ticker COGT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,758,300
Market Cap $612M
Description
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found ...

Get notified when there are updates to the investment portfolio of E Fund Management Co., Ltd., based on Form 13F filings with the SEC.

Stay updated on E Fund Management Co., Ltd. with notifications on news.